Maravai LifeSciences Strategy and Business Model

Executive Overview

Maravai LifeSciences is a specialized life-sciences tools company that sells the inputs, reagents, and analytical products used to develop and manufacture nucleic-acid-based therapies, vaccines, diagnostics, and biologic drugs. Formed in 2014 and headquartered in San Diego, California, Maravai built its portfolio largely through acquisitions, with TriLink BioTechnologies anchoring its nucleic acid production business and Cygnus Technologies anchoring biologics safety testing. The company’s strategy is not to be a broad commodity lab supplier. Instead, it focuses on higher-value, workflow-critical products such as mRNA capping analogs, modified nucleotides, custom RNA manufacturing services, specialized enzymes, and impurity-detection assays that can become embedded in customer development and quality systems.

That positioning can create better pricing and stickier demand than general-purpose research reagents, but revenue can still be volatile because customer program timing, biotechnology funding conditions, and vaccine-related demand are uneven. Maravai sells globally, although its physical operating footprint remains concentrated in the United States. In FY2024, Maravai reported #N/A of revenue, well below its pandemic-era peak but more representative of the underlying core businesses it is trying to scale over time.

Maravai LifeSciences at a Glance

Logo
Common name	Maravai
Full legal name	Maravai LifeSciences Holdings, Inc.
Headquarters	San Diego, California, United States
Ownership	Publicly traded; Nasdaq-listed. Ownership is primarily public-market and institutional. GTCR was the private-equity sponsor that formed the company.
Ticker	MRVI
Exchange	NASDAQ
Market Cap	$1.39B
Revenue (FY2024)	#N/A
Founding / major historical milestones	Formed in 2014; initial public offering in 2020; expanded through acquisitions including Cygnus, Glen Research, Alphazyme, and MyChem; experienced major pandemic-era demand tied to mRNA supply, followed by normalization.
Industry or industries	Life sciences tools; nucleic acid production; biologics safety testing
Key products or services	mRNA capping analogs, modified nucleotides, custom RNA and oligonucleotide manufacturing, specialized enzymes, nucleic acid chemistry reagents, host-cell-protein assays, impurity testing reagents, analytical support
Geographic footprint	Global customer base with operations concentrated in the United States and international distribution into Europe, Asia-Pacific, and other life-sciences markets
Business segments as officially reported	Nucleic Acid Production; Biologics Safety Testing
Company website	https://www.maravai.com/

1. What Is the Strategy of Maravai?

1. 1a. What is the winning aspiration of Maravai?

   Maravai’s public materials frame the company as an enabling supplier to the biotechnology and biopharmaceutical ecosystem rather than as a drug developer. Its aspiration is to become a trusted provider of critical products used in the development and manufacture of nucleic-acid therapeutics, vaccines, diagnostics, and biologic drugs. In practical terms, “winning” for Maravai means being designed into customer workflows where performance, regulatory support, documentation, and lot consistency matter more than lowest price. After the unwind of extraordinary pandemic-era demand, management’s near-term aspiration has been to restore sustainable growth in its core businesses and rebuild profitability from a normalized base. Maravai has not consistently anchored that aspiration to one evergreen long-range revenue target in post-pandemic materials; the emphasis has instead been on durable growth, sharper portfolio focus, and disciplined capital deployment.

2. 1b. Where does Maravai play?

   Maravai plays in two adjacent but distinct markets. First, it serves nucleic acid production, where customers need capping analogs, modified nucleotides, custom RNA, oligonucleotide chemistry, enzymes, and related inputs for mRNA therapeutics, vaccines, diagnostics, gene editing, and other nucleic-acid applications. Second, it serves biologics safety testing, where biologic drug manufacturers need assays and reagents to detect impurities such as host cell proteins and residual manufacturing contaminants. Maravai focuses on life-sciences customers that value technical performance and regulatory-grade support: large biopharma, emerging biotech, contract development and manufacturing organizations, diagnostics developers, and research institutions. Geographically, it sells globally, but its operations are mainly U.S.-based.

3. 1c. How does Maravai plan to win?

   Maravai’s approach is differentiation, not scale-driven cost leadership. It aims to win through proprietary or hard-to-replicate chemistry, strong product performance, quality systems suitable for research and Good Manufacturing Practice-supporting workflows, and technical support that helps customers move from research into clinical and commercial supply. Products such as CleanCap and the broader TriLink portfolio illustrate this model: they are valuable because they improve workflow outcomes and can become embedded in customer process design. Maravai also tries to deepen its position by owning adjacent capabilities through acquisitions such as Alphazyme and MyChem, which appear intended to broaden internal chemistry and enzyme capabilities and reduce dependence on third parties. In biologics safety testing, the company competes on validated assays, scientific reputation, and the cost of switching once a customer has standardized a testing workflow.

4. 1d. What capabilities must Maravai have in place?

   To support that strategy, Maravai needs advanced nucleic acid chemistry, enzymology, assay development, application science, and regulatory-quality manufacturing. It also needs strong quality-management systems, analytical testing, change-control discipline, documentation, and tech-transfer capability because customers in therapeutic manufacturing are sensitive to qualification risk. Operationally, Maravai must be able to produce both catalog products and custom materials, often in smaller batches with high consistency requirements. Commercially, it needs technically credible sales teams that can engage scientists, process-development teams, quality groups, and procurement functions. Finally, because Maravai was assembled through acquisitions, it needs integration capability so that the group functions as a coherent platform rather than a loose collection of brands.

5. 1e. What management systems does Maravai require?

   Maravai needs management systems built around quality, portfolio discipline, and capital allocation. That includes segment-level operating reviews, quality and compliance oversight, capacity and inventory planning, and customer-program forecasting for a demand base that can be lumpy. It also requires careful stage-gating for capital projects, product development, and acquisitions, because overbuilding for temporary demand can hurt margins later. Since post-pandemic demand has been less predictable than at the COVID peak, cost control and utilization management matter more than they did during the surge. An external synthesis from management commentary is that Maravai’s management systems now need to balance growth investment with tighter operating discipline.

2. What Are the Current Strategic Initiatives of Maravai?

• Expand nucleic acid production beyond COVID-linked demand. Maravai has been repositioning its nucleic acid business toward the broader therapeutic and diagnostic pipeline, including mRNA therapeutics, gene editing, oligonucleotide applications, and other nucleic-acid modalities. The strategic goal is to reduce dependence on unusual pandemic demand and build a more diversified base of therapeutic-development programs.
• Deepen upstream capability in critical inputs. The acquisitions of Alphazyme and MyChem suggest a strategic push to control more of the enzyme and chemistry stack that supports nucleic acid production. This matters both for supply assurance and for margin capture in technically specialized inputs.
• Invest in custom and GMP-supporting offerings. Maravai’s most strategically valuable opportunities are typically not off-the-shelf commodities; they are custom or regulated-workflow products that customers qualify into development and manufacturing. Building those capabilities can support stickier, longer-lived revenue if customer programs progress.
• Grow biologics safety testing through broader assay relevance. Cygnus gives Maravai a position in a repeat-driven testing market. The opportunity is to broaden assay coverage across biologics, vaccines, and newer modalities while leveraging the company’s installed reputation in quality-control workflows.
• Improve cost structure and operating efficiency after normalization. Maravai’s public messaging after the pandemic demand unwind has emphasized aligning the cost base with a more normalized revenue level. That includes productivity, expense discipline, and better utilization of manufacturing and support resources.
• Use selective M&A to add capabilities rather than simply add revenue. Maravai’s deal history implies that acquisitions are most attractive when they add strategic adjacency, such as upstream inputs, enabling technologies, or stronger positions in quality-sensitive workflows.

3. What Is the Business Model of Maravai?

What customers actually buy

Customers buy specialized products that help them create, test, or manufacture complex biologic and nucleic-acid products. In nucleic acid production, that includes capping analogs, modified nucleotides, enzymes, custom RNA and oligonucleotide materials, and research-use as well as manufacturing-support inputs. In biologics safety testing, customers buy assay kits, antibodies, analytical reagents, and related tools used to detect process impurities and validate product safety.

Recurring versus one-time revenue

Maravai is not a subscription business. Revenue comes primarily from product sales and custom project work. The repeat profile varies by product line. Cygnus’s assay and testing reagent business is relatively repeat-driven because customers perform recurring quality-control and process-monitoring work. By contrast, custom nucleic-acid manufacturing can be more program-based and lumpy, especially during early development. That said, once a reagent or material is qualified into a clinical or commercial manufacturing process, demand can become very sticky.

How pricing power works

Pricing power tends to come from product performance, intellectual property, technical support, and switching costs created by process validation. A customer using a specialized Maravai input in a regulated workflow may face significant comparability work if it changes suppliers. That can support healthier pricing than a commodity reagent business would allow. Pricing power is weaker in more standardized catalog products and can be offset by competition or customer purchasing scale.

Why the business mix matters

Business mix matters because proprietary, regulated-workflow, and custom products generally carry better economics than basic research reagents. Cygnus’s repeat testing business can provide stability, while TriLink-led nucleic acid production can offer more strategic upside but more volatility. During the pandemic, one part of the portfolio briefly became extraordinarily large; the post-pandemic period has made the underlying mix much more important to understanding earnings quality.

What drives gross margin, operating margin, and cash generation

Gross margin is driven by product mix, proprietary content, manufacturing yields, and facility utilization. When volumes fall, under-absorption can pressure margins even if unit economics remain attractive. Operating margin depends on how efficiently Maravai runs technical sales, R&D, quality, and corporate overhead relative to revenue. Cash generation is influenced by working-capital discipline, inventory planning for lumpy customer programs, and the pace of capital spending on manufacturing and capability expansion.

Revenue model

Maravai’s revenue model is best described as a mix of catalog product sales, custom manufacturing and development work, and repeat analytical reagent sales. It is not recurring in the software sense, but parts of the portfolio are repeat-driven and can become embedded in long-lived customer workflows.

4. What Products and/or Services Does Maravai Sell?

Maravai sells a focused set of life-science enabling products rather than broad laboratory consumables.

• Nucleic acid production products. Through businesses such as TriLink, Glen Research, Alphazyme, and MyChem, Maravai offers mRNA capping analogs, modified nucleotides, phosphoramidites, nucleic acid chemistry reagents, specialty enzymes, and custom RNA-related manufacturing support.
• Custom development and manufacturing support. For therapeutic and vaccine developers, Maravai provides custom materials and process-support products used in research, preclinical work, and later-stage manufacturing workflows.
• Biologics safety testing products. Through Cygnus, Maravai supplies host-cell-protein antibodies, enzyme-linked immunosorbent assay kits, residual impurity testing reagents, and other analytical tools used by biologics manufacturers and quality-control laboratories.
• Research-use catalog reagents. Parts of the portfolio, especially legacy chemistry products, serve academic and industrial research workflows and provide a broader funnel into development-stage customers.

The most strategically important offerings appear to be the higher-value nucleic acid production products and custom services that can become embedded in therapeutic-development workflows. Historically, those products drove the company’s pandemic-era surge and remain central to its long-term growth thesis. Cygnus’s biologics safety testing products appear especially important as a steadier, repeat-driven counterweight. A useful distinction is between legacy catalog chemistry products, which support the research base, and newer growth offerings tied to mRNA, gene editing, and regulated manufacturing support.

5. What Are the Key Competitors or Peers of Maravai?

Maravai does not have one perfect one-for-one competitor because it competes in specific niches within life-science tools. Its competitive set differs by segment.

• Danaher — Through businesses such as Integrated DNA Technologies and Aldevron, Danaher competes in synthetic nucleic acids, plasmids, GMP-grade inputs, and adjacent bioprocess workflows.
• Thermo Fisher Scientific — A broad life-science tools leader with offerings across molecular biology reagents, oligonucleotides, enzymes, bioproduction inputs, and analytical workflows.
• Merck KGaA / MilliporeSigma — Competes across specialty chemicals, molecular biology reagents, process materials, and manufacturing-support tools relevant to nucleic-acid and biologics workflows.
• New England Biolabs — A strong competitor in enzymes and molecular biology reagents used in nucleic-acid workflows, especially in research and development settings.
• Twist Bioscience — An important peer in synthetic DNA and oligonucleotide-related workflows, with more emphasis on gene synthesis and synthetic biology.
• Bio-Rad Laboratories — Competes in assay reagents, antibodies, analytical tools, and quality-control workflows that overlap parts of biologics safety testing.
• Bio-Techne — A peer in specialized reagents and cell-and-gene-therapy-related tools, more adjacent than identical but relevant in high-value research and bioprocess workflows.
• Charles River Laboratories — More of a substitute in outsourced testing and analytical services than a direct product competitor, but relevant where customers can buy services rather than in-house tools.
• Sartorius — Primarily a bioprocessing and lab-tools company, but a relevant adjacent competitor in biologics-manufacturing workflows and quality-sensitive production environments.

The most direct competition for Maravai’s nucleic acid business comes from larger tools companies with broader manufacturing and distribution scale. In biologics safety testing, the competitive set includes both reagent suppliers and outsourced testing alternatives. Maravai’s advantage is usually niche depth and workflow specificity rather than breadth.

6. What Is the Marketing Strategy of Maravai?

Maravai’s marketing is fundamentally scientific and account-based. It does not rely on mass-market brand advertising. Instead, the company markets through technical content, application data, scientific conferences, webinars, publications, distributor relationships, and specialist sales teams that can engage researchers, process-development scientists, and quality groups. Brand credibility matters at the bench and in manufacturing support, so marketing is closely tied to technical validation rather than image. For products used in regulated or near-regulated workflows, marketing also depends on documentation quality, reproducibility data, and the ability to help customers understand how a product will perform in their process.

In that sense, marketing is an important supporting capability rather than the core differentiator. The core differentiators are product performance, scientific reputation, and workflow fit. Marketing’s role is to convert those strengths into qualified demand, especially in high-potential therapeutic accounts and international channels.

7. What Are the Key Customer Segments of Maravai?

• Biopharmaceutical companies. These include large pharmaceutical companies and emerging biotechs developing mRNA therapeutics, vaccines, biologics, gene-editing products, and related modalities.
• Contract development and manufacturing organizations. CDMOs matter because they buy or specify many of the materials and assays used in outsourced development and production.
• Diagnostics developers and manufacturers. Maravai’s nucleic acid inputs are relevant to assay and diagnostic workflows, especially where high-performance nucleic acid chemistry is required.
• Quality-control and process-development laboratories. Cygnus products are used by manufacturers that must monitor process impurities and product safety.
• Academic and government research institutions. These customers matter more for catalog reagents and early-stage scientific adoption than for the highest-value commercial volumes.

Maravai is diversified across customer types within life sciences, but it can still become exposed to concentration when a few large therapeutic or vaccine programs scale up or down. That is a defining feature of the business: customer diversity exists, yet revenue concentration can still rise when marquee programs become unusually large.

8. What Is the Sales Model of Maravai?

Maravai uses a mixed sales model. Large or technically complex accounts are usually served through direct sales supported by scientific and application specialists. That is especially important for custom nucleic-acid materials and products that may be qualified into clinical or commercial workflows. Standard catalog products can be sold through inside sales, e-commerce, and distribution partners. Internationally, distributors appear to play a meaningful role, particularly for research-use products and smaller accounts.

The channel structure affects growth and pricing in important ways. Direct sales improve customer intimacy, make co-development easier, and support premium pricing where the product is technically critical. Distributor channels broaden reach but can reduce control over the customer relationship. For Maravai, the most valuable accounts are usually not transactional catalog buyers; they are customers with long qualification cycles and high switching costs once a product is designed in.

9. In What Geographies Does Maravai Operate?

Maravai serves customers globally, but its operating footprint is centered in the United States. San Diego is the corporate center and a major hub for TriLink-related activities. Other operating sites tied to acquired businesses are in the United States as well, including facilities associated with Cygnus in North Carolina and Glen Research in Virginia. The company’s physical footprint is therefore more concentrated than its revenue footprint.

Commercially, Maravai reaches customers across North America, Europe, and Asia-Pacific through a combination of direct sales and distributor relationships. That global reach matters because therapeutic development and biologics manufacturing are internationally distributed, even when the company’s manufacturing base is not. From a strategy standpoint, Maravai is better described as a U.S.-based platform with global customers than as a geographically balanced multinational manufacturer.

10. Who Are the Owners of Maravai?

Maravai is a public company listed on Nasdaq under the ticker MRVI. Based on public filings in 2024, ownership is largely institutional and dispersed among public-market investors. GTCR, the private-equity firm that formed Maravai in 2014, was historically an important shareholder after the 2020 initial public offering, while large asset managers such as BlackRock and Vanguard have also appeared among significant holders in public-market disclosures. There is no indication of government ownership or a controlling state stake.

11. How Is Maravai Organized?

At a practical level, Maravai is a holding company built from specialist operating businesses. As of FY2024, it reports two principal segments:

• Nucleic Acid Production — centered on brands such as TriLink, Glen Research, Alphazyme, and MyChem.
• Biologics Safety Testing — centered on Cygnus.

That reporting structure is important because the economics and demand patterns of the two segments differ. Nucleic Acid Production is more exposed to large program swings but also to higher-growth therapeutic markets. Biologics Safety Testing is more repeat-driven and closer to a quality-control consumables model. Legally, Maravai still reflects the legacy entities it acquired. Operationally, it is managed more like a portfolio of specialist businesses supported by a corporate center for finance, legal, human resources, strategy, and capital allocation.

12. How Does Maravai Operate?

Maravai operates by sourcing specialized raw materials, synthesizing or formulating high-value reagents, performing analytical and quality-control testing, and delivering finished products to research, development, and manufacturing customers. In nucleic acid production, this can include chemistry-intensive synthesis, enzyme-related processes, purification, documentation, and release testing. In biologics safety testing, operations include antibody and assay development, kit production, validation support, and quality-controlled distribution.

Operational complexity comes from several sources. First, the company serves both research and manufacturing-support markets, which require different documentation and quality expectations. Second, demand can be lumpy because customer programs do not scale smoothly. Third, any change in raw materials, process conditions, or product specifications can create qualification issues for customers. For Maravai, day-to-day excellence is less about massive manufacturing scale than about consistency, technical responsiveness, traceability, and the ability to meet demanding customer specifications.

13. What Are the Growth Opportunities for Maravai?

Maravai’s most plausible growth opportunities are closely tied to public management commentary and to the structure of its portfolio.

• Broader mRNA and nucleic-acid therapeutics adoption. The largest opportunity is continued expansion of mRNA and adjacent modalities beyond COVID vaccines into cancer, rare disease, protein replacement, and other therapeutic categories.
• Gene editing, oligonucleotide therapeutics, and related modalities. Maravai’s chemistry and enzyme capabilities can support multiple nucleic-acid platforms, not just mRNA.
• Deeper participation in later-stage and commercial supply. If Maravai products are qualified into programs that progress clinically, revenue can become more durable and larger per program.
• Expansion of biologics safety testing. Cygnus has room to deepen its relevance in biologics quality control, including newer therapeutic modalities that still need impurity and safety monitoring.
• Cross-selling and portfolio adjacency. Maravai can potentially sell more upstream chemistry, enzymes, and analytical products into the same customer accounts.
• Selective acquisitions. The company’s history suggests additional tuck-in deals could extend technology depth or customer relevance.

The main constraints are also clear: biotechnology funding cycles, customer inventory corrections, uneven program timing, competition from much larger tools companies, and the operational challenge of matching capacity to uncertain demand. An external synthesis is that Maravai has a credible growth runway, but only if it can convert scientific relevance into a broader and more stable customer base than it had during the pandemic-driven spike.

14. What Is the History of Maravai?

Maravai was formed in 2014 by GTCR as a life-science tools platform. An important nuance is that the holding company is relatively young, while several of its operating businesses are much older specialist brands. Over time, Maravai assembled its portfolio through acquisitions, most notably TriLink as the foundational nucleic-acid business, Cygnus in biologics safety testing, Glen Research in nucleic-acid chemistry, Alphazyme in enzymes, and MyChem in upstream chemistry.

Maravai went public in 2020. Its profile rose sharply during the pandemic because TriLink’s products were relevant to mRNA vaccine and therapeutic manufacturing. That created an extraordinary but temporary revenue surge that made Maravai far larger and more visible than its pre-pandemic base would have implied. The next phase of the company’s history has been defined by normalization: lower vaccine-related demand, greater focus on underlying core markets, tighter cost control, and a sharper emphasis on building a durable life-science tools company rather than managing a one-time windfall.

15. What Are the Key Suppliers to Maravai?

Suppliers matter to Maravai because its products depend on specialized chemistry and high-consistency manufacturing inputs. The most important supplier categories likely include specialty nucleosides and phosphoramidites, enzyme-related raw materials, purification media, single-use bioprocess consumables, plastics, analytical components, packaging, and temperature-controlled or otherwise carefully managed logistics. For a company serving development and manufacturing workflows, lot traceability and change control are strategically important; a seemingly small supplier change can create downstream qualification issues for customers.

Maravai’s acquisitions of Alphazyme and MyChem appear strategically relevant in this context because they help internalize capabilities that might otherwise sit with suppliers. That can improve supply assurance, quality control, and margin capture. Supplier structure matters most where an input is technically specialized, sole-sourced, or difficult to replace quickly.

16. What Are the Key Brands Owned by Maravai?

For Maravai, operating brands matter a great deal because many scientific buyers know the product brand better than the holding-company name.

• TriLink BioTechnologies — Maravai’s flagship nucleic acid production brand, associated with CleanCap, custom RNA-related services, and specialized nucleic-acid inputs. This is the most visible strategic brand in the portfolio.
• Cygnus Technologies — The key biologics safety testing brand, known for host-cell-protein assays and impurity-testing reagents used in biologics development and manufacturing.
• Glen Research — A well-known brand in nucleic acid chemistry reagents, particularly for research and development workflows.
• Alphazyme — A specialized enzyme brand that broadens Maravai’s upstream capabilities in nucleic-acid workflows.
• MyChem — Adds modified nucleoside and related chemistry capabilities that support the nucleic acid production stack.

Branding is a meaningful strategic lever for Maravai because trust in a scientific brand can influence adoption, especially when buyers care about technical reproducibility and support quality.

17. How Does the Supply Chain of Maravai Function?

Maravai’s supply chain starts with specialized raw-material sourcing and moves through chemistry or reagent production, purification, analytical testing, inventory control, and shipment to global customers. The supply chain differs by product. Catalog reagents can be made to stock, but custom or manufacturing-support products often require tighter planning and longer lead times. For quality-sensitive products, documentation, release testing, chain of custody, and packaging controls can be as important as physical production.

Supply-chain reliability matters strategically because customers may be running development timelines or manufacturing campaigns that cannot absorb delays easily. Flexibility also matters: Maravai must manage both relatively predictable repeat demand in safety-testing reagents and more volatile project-driven demand in nucleic-acid production. This makes sales and operations planning, inventory discipline, and supplier qualification unusually important for a company of its size.

18. What Is the R&D Strategy of Maravai?

Maravai’s research and development strategy is applied and workflow-oriented rather than drug-discovery oriented. The company invests in improving reagent performance, expanding chemistry and enzyme capabilities, developing new assays, and creating products that help customers move from research into regulated manufacturing. In nucleic acid production, that means innovation in capping chemistry, modified nucleotides, enzymes, and process-relevant inputs. In biologics safety testing, it means new assay coverage, stronger impurity detection tools, and methods that fit emerging biologic modalities.

R&D is strategically important because differentiation depends on technical performance and because customers are willing to pay more for products that solve hard workflow problems. Maravai’s innovation model appears to be close to the customer: develop products that fit real manufacturing and analytical pain points, then support adoption with data and technical service.

19. What Is the Finance Strategy of Maravai?

Maravai’s finance strategy has necessarily changed since the pandemic peak. During the surge, the company benefited from unusually strong volumes and cash generation. In the more normalized period that followed, the finance challenge became preserving balance-sheet flexibility, resizing the cost base, and funding the right growth investments without assuming pandemic demand would return. Publicly, that has meant a greater emphasis on operating discipline and selective capital deployment.

At a high level, Maravai’s capital allocation logic appears to be: protect liquidity, invest in high-value core capabilities, use M&A selectively where it strengthens the nucleic-acid or safety-testing portfolio, and avoid treating temporary demand spikes as a permanent earnings base. The company does not fit the profile of a mature dividend story; its finance strategy is more about reinvestment, margin recovery, and disciplined portfolio shaping.

20. What Major Acquisitions Has Maravai Made?

Acquisitions have been central to how Maravai was built. The company’s M&A pattern suggests a capability-building strategy rather than a pure roll-up of unrelated assets.

M&A has therefore played three roles for Maravai: building the original platform, expanding technical depth in adjacent inputs, and shaping the portfolio toward higher-value workflow positions. An external synthesis is that future deals are likely to be judged less on headline scale and more on how well they deepen Maravai’s position in nucleic-acid production or biologics safety testing.

21. How Companies Like Maravai Leverage Independent Consultants through Umbrex

Umbrex has grown a global community of over 8,000 independent management consultants who are based in more than 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top consulting firms. Companies like Maravai engage Umbrex when they need talent with the training those firms provide but do not need a full consulting team with the associated overhead. For a company like Maravai, the best use cases are usually focused, high-value projects tied to growth, operations, portfolio decisions, and capability building.

• Core growth strategy for nucleic acid production — market sizing and prioritization across mRNA therapeutics, gene editing, oligonucleotide therapeutics, diagnostics, and adjacent modalities.
• Commercial segmentation and account prioritization — identify the most attractive biopharma, CDMO, and diagnostics accounts for TriLink, Cygnus, and the broader Maravai portfolio.
• Pricing and packaging strategy — redesign pricing architecture for proprietary inputs, custom GMP-supporting work, and repeat assay products to better reflect value and switching costs.
• Sales model redesign — optimize the balance among direct strategic-account selling, application support, inside sales, e-commerce, and distributor channels.
• Manufacturing footprint and capacity planning — determine where Maravai should add capacity, what should be made internally, and how to align fixed cost with highly variable demand.
• Procurement and supply-risk reduction — strengthen sourcing strategy for critical chemistry inputs, enzymes, single-use materials, and other high-risk components.
• Margin-improvement program — analyze product mix, utilization, overhead allocation, and workflow redesign to improve gross margin and operating leverage in a normalized demand environment.
• M&A target screening and diligence support — identify tuck-in acquisition targets in nucleic-acid chemistry, enzymes, analytical tools, or international distribution and support integration planning.
• Biologics safety testing growth plan — build a go-to-market and product-expansion roadmap for Cygnus in cell therapy, gene therapy, and other newer biologic modalities.
• ERP, data, and AI-enabled planning initiatives — improve demand forecasting, inventory planning, customer profitability analysis, and technical knowledge management across acquired businesses.